Brainstorm Cell Therapeutics issues $182,400 convertible note to Vanquish Funding

BRAINSTORM CELL THERAPEUTICS INC.

Issued $182,400 promissory note (incl. $22,400 OID) to Vanquish Funding; net proceeds ~$155,000 after $5,000 fees.
Note bears 12% interest (22% if unpaid), matures August 30, 2026; convertible at 35% discount to lowest 10-day trading price.
Additional tranches up to $2M available over 12 months subject to further agreement with Vanquish.
Conversion shares subject to 4.99% beneficial ownership cap; issued under Section 4(a)(2) exemption.
Proceeds will be used for general working capital purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.